Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Neoplasms × Exenatide × 30 days × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Gemcitabine 17 Specimen Handling 11 130-nm albumin-bound paclitaxel 10 pembrolizumab 9 Magnetic Resonance Spectroscopy 8 Albumin-Bound Paclitaxel 7 Leucovorin 6 Fluorouracil 6 Biopsy 6 Taxes 5 Irinotecan 5 Cyclophosphamide 5 Cetuximab 5 fludarabine 4 Carboplatin 4 olaparib 3 dehydroftorafur 3 Radiosurgery 3 Oxaliplatin 3 zimberelimab 2 trastuzumab deruxtecan 2 quemliclustat 2 irinotecan sucrosofate 2 durvalumab 2 aldesleukin 2 Tadalafil 2 Pemetrexed 2 Immunoglobulin G 2 Erlotinib Hydrochloride 2 Disulfides 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05663515 2026-03-19

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡